PPA2

Across TCGA pan-cancer cohorts, PPA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPA2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PPA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PPA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where PPA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.660	0.344	<.001	26	view →
COAD	DFS	Median	All	1.000	0.921	.016	24	view →
CCRCC	DFS	Tertile	II,III,IV	0.436	0.826	.008	7	view →
LSCC	DFS	Tertile	All	0.611	0.833	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPA2–PDAC (OS)

Open the PDAC breakdown →